Tag Archives: Health Care

Partnership for Part D Access Launches Today

BIO-logo-115x76

BIO joins patient groups and other health care stakeholders today to announce the formation of the Partnership for Part D Access, a coalition committed to protecting access to necessary medications for patients in the Medicare Part D prescription drug program. The Partnership for Part D Access opposes a proposed rule from the U.S. Centers for Medicare & Medicaid Services (CMS) that would reduce the number of “protected classes” of medication in Medicare Part D, specifically Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Physician Payments Sunshine Act: Collaboration Key for Doctors & Biopharmas

Jim Greenwood

In a letter to the editor on USA Today, BIO CEO Jim Greenwood and John J. Castellani, president of PhRMA, write that context must accompany the data being provided under the Physician Payments Sunshine Act: “Discovery of new and improved medicines would be impossible without collaborations between physicians and biopharmaceutical companies. Consider ongoing research and clinical trials that not only make medicines possible, but also help our understanding of disease. Biopharmaceutical professionals help physicians stay Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

National Health Interview Survey: Adult Vaccination Rates Need Boost

Copyright sanofi pasteur

The Centers for Disease Control and Prevention (CDC) recently released immunization coverage estimates from the 2012 National Health Interview Survey (NHIS) for six vaccines routinely recommended for adults including pneumococcal, tetanus and Tdap, Hepatitis A, Hepatitis B, herpes zoster (shingles), and Human papillomavirus (HPV). These data indicate little overall improvement in vaccination coverage among adults from 2011 to 2012. Compared with 2011, modest increases occurred in three vaccines: Tdap, herpes zoster and HPV. However, vaccination Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

4 Tips for Building a Successful Biotech: Richard Pops of Alkermes at #BIOCEO14

Pops

The 16th Annual BIO CEO & Investor Conference opened with a fireside chat between Richard F. Pops, Chairman & Chief Executive Officer of Alkermes, and David Gluckman of Lazard. The candid discussion gave biotech CEOs a peek in to the story of Alkermes, yielding useful guidance on building a successful, agile company ready for a changing marketplace. Here are some of the highlights: Be world class in a specific area of science. “In our company, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

FDA Week: For Biologics, A Name Isn’t Just A Name (Jim Greenwood op-ed)

Jim Greenwood

What is in a name? Names help make medicinal products more easily distinguishable by doctors, pharmacists and patients. When you are talking about biologics, complex medicines that are manufactured using living organisms, and biosimilars, medicines that are similar to, but not the same as, innovator biologics, naming is a significant consideration. As a pathway for biosimilars approval is implemented, a clear priority should be to craft a naming convention that both contributes to patient safety Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,